IDH1 and neoplasm: OS was compared for a variety of subsets defined by the patient (age, KPS), tumor characteristics (MGMT promoter methylation and IDH1/2 mutation status), or anti-cancer therapy (number and cell composition of vaccinations received, TTF and/or bevacizumab use, and corticosteroid use).